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Quality of life QOLAbstract Introduction: In Meniere’s disease, medical treatment consists of salt restriction,
vasodilators, diuretics, and symptomatic therapy for the nausea and diaphoresis associated with
spells of vertigo. If medical treatment fails, other modalities of treatment should be considered.
The aim of this study is to assess the efﬁcacy of intratympanic dexamethasone in such failed cases.
Patients and methods: The study was done in 2 centers: Jordan University Hospital/Amman/Jordan,
and the Consultation Center of Nineveh Medical College/Nineveh/Iraq, in the period from 2009 to
2014. Twenty-ﬁve patients with Meniere’s disease who did not respond to medical treatment were
managed by intratympanic dexamethasone for at least 3 months. The follow up period was from 1
to 5 years. The response was quantiﬁed by assessing the quality of life improvement. Results: The
age of the patients ranged from 28 to 58 years with mean ± SD (43.84 ± 8.80) years. There were 12
(48%) males and 13 (52%) females. Clinical improvement was reported in 22 patients with overall
success rate (88%). Statistical analysis shows a signiﬁcant improvement in the quality of life after
the therapy. The improvement was overall and mainly with vertigo symptoms. The improvement
in hearing and tinnitus was minimal. Conclusion: Intratympanic dexamethasone for Meniere’s dis-
ease is very satisfactory if medical treatment fails with good vertigo control and no risk to hearing.
 2016 Egyptian Society of Ear, Nose, Throat and Allied Sciences. Production and hosting by Elsevier B.V.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).1. Introduction
Meniere’s disease is an inner ear disorder of episodic vertigo,
sensorineural hearing loss, aural fullness, and tinnitus that
affects approximately 15 out of every 100,000 individuals in
the United States, with similar values of prevalence reported
throughout the world.1According to the guidelines of the American Academy of
Otolaryngology- Head and Neck Surgery committee on hear-
ing and equilibrium, diagnosis of Meniere’s disease is based
on clinical symptoms and exclusion of identiﬁable ‘‘other
causes”. Four degrees of diagnostic certainty are deﬁned: cer-
tain, deﬁnite, probable and possible Meniere’s disease. Deﬁnite
Meniere’s disease is identiﬁed by 2 deﬁnite spontaneous epi-
sodes of vertigo lasting longer than 20 min, audiometrically
documented hearing loss on at least one occasion, and tinnitus
or aural fullness.2
Medical treatment consisting of salt restriction, vasodila-
tors, diuretics, and symptomatic therapy for the nausea and
64 B.M.N. Saeed et al.diaphoresis associated with spells of vertigo allows controlling
the disease in as many as two-thirds of the patients. When
medical therapy fails to reduce the recurrent spells of vertigo,
other treatment options should be considered.3
Autoimmunity is a strong etiology and some investigations
demonstrated immunological abnormalities in Meniere’s dis-
ease.4,5 Therefore, the beneﬁcial effects of steroids could be
due to their anti-inﬂammatory and immunosuppressive effects.
Now intratympanic steroid injections have been proposed as
the initial procedure of choice.6,7
The aim of our study is to assess the efﬁcacy of intratym-
panic dexamethasone in patients who failed to respond to
medical treatment and vertigo is the main problem.
2. Patients and methods
This is a retrospective analysis of patients who underwent
intratympanic dexamethasone therapy for Meniere’s disease.
The study was done in 2 centers: Jordan University Hospi-
tal/Amman/Jordan, and The Consultation Center of Nineveh
Medical College/Nineveh/Iraq.
Patients with deﬁnite Meniere’s disease according to the
guidelines mentioned above were assessed.2 Neurotological
evaluation of patients included a full ENT examination, audio-
logical and vestibular assessments. Ear examination by oto-
scopy and tuning fork testing was routinely done in the clinic.
Hearing was assessed by means of pure tone audiometry and
tympanometry was done to assess the compliance of the middle
ear. Body balance assessment included the Romberg andUnter-
berger–Fukuda tests, positional and positioning nystagmus.
The diagnosis was mainly clinical based on the history of
episodic attacks of vertigo, aural fullness and tinnitus, and
the evidence of sensorineural hearing loss by pure tone audio-
gram. All patients underwent an MRI scan to rule out reto-
cochlear pathology mainly vestibular Shwanoma. The
elecrocochleographic test is not available in our centers.
The research was approved by the Ethics Committee of the
scientiﬁc department and informed consent was taken from all
the participants.
Patients who had no improvement of symptoms of MD,
especially vertigo attacks (frequency and severity) despite med-
ical treatment for at least 3 months were enrolled in this study.
Medical treatment included mainly betahistine hydrochloride
(Betaserc) tablets 16 mg three times daily, together with salt
restriction and diuretics, Moduretic (50 mgs hydrochlorthi-
azide, and 5 mgs amiloride), one tablet/day in medically free
patients in whom diuretics are not contraindicated.
3. Procedure
Myringotomy and grommet insertion was done under local
anesthesia in the ENT clinic. A cotton piece soaked with
10% Xylocaine (Astrazeneca) was kept in the ear canal in con-
tact with the tympanic membrane for about 30 min. The grom-
met was inserted in the posteroinferior quadrant. The ﬁrst
intratympanic steroid injection was done in the clinic. Dexam-
ethasone (8 mg/2 cc) ampoule was instilled into the ear by
slowly syringing through the tube, and patients remained
supine with the head angled slightly head down and turned
to the contralateral side for 30 min to continually bathe the
round window with dexamethasone. Follow ups in the ENTclinic were scheduled one week, 2 weeks, and then monthly
for 3–6 months, in which dexamethasone 8 mg was injected
in a similar manner to the ﬁrst one. Besides, the medication
was self-administered by the patient at home using dexametha-
sone eye drops (Maxidex 0.1%, Alcon). The patients were
instructed to lie on their side with the affected ear upright,
and place 5 drops into the ear while pulling the auricle out-
ward. After the instillation, the tragus was pressed repeatedly
to ensure the passage of the medication into the middle ear,
and this position was kept for 15 min.
This was done thrice daily for one week, then every other
day for a second week. Then the dexamethasone was instilled
twice weekly for 3–6 months. This maintenance dose was kept
as long as the grommet was in the ear, with a total period of
therapy ranging from 6 to 12 months.
Patients were instructed to avoid water entry into the ear,
and to report once they feel ear block, discharge or otalgia
which might signify infection.
Follow up period extended form 1 to 5 years (average
2.5 years), during which a routine ENT examination was done,
especially ear examination and checking the status of the
grommet. In 2 patients the grommet was reinserted after its
extrusion before completing 3 months of therapy.
In cases of bilateral MD, the procedure was ﬁrstly done in
the ear which is more symptomatic (ear block and tinnitus)
which is the worse hearing ear, and if no improvement took
place within 3 months, the second ear was dealt with similarly
and bilateral ear therapy was done. Bilateral intubation was
needed in 2 patients with bilateral MD.
A questionnaire was given to all patients to assess the score
of improvement regarding the vertigo, hearing and physical
health. The questionnaire was based on Meniere’s disease out-
come questionnaire invented by Kato et al.8
The questionnaire consists of 40 questions including before
and after the therapy. In the questionnaire there are questions
about vertigo and unsteadiness (vertigo score), hearing and
tinnitus (hearing score), and questions about daily activity
and physical health (physical score). The answers of the ques-
tions are scored from (0 to 4), as (0) is given as the lowest score
and (4) as the maximum score.
We included 38 questions in the interview with patients
about 3–6 months after the therapy. The improvement to ther-
apy was decided by abolition or reduction of vertigo attacks
and/or unsteadiness symptoms, together with improvement
of the general well being and physical health. Audiogram
was done to all patients as a diagnostic tool. As many patients
did not do the requested post evaluation audiogram, it was not
included in the evaluation score.4. Results
The age of the patients ranged from 28 to 58 years with mean
± SD (43.84 ± 8.80) years. There were 12 (48%) males and 13
(52%) females. The duration of illness ranged from 1 to 7 with
mean of 3 years. The sites of Meniere’s disease were right sided
in 11 (44%), left sided in 7 (28%) and bilateral in 7 (28%) of
patients. The mean pure tone average of the frequencies
(250, 500, 1000, and 2000) was 49.8 dbs. Table 1 show the
patients’ demographics, with their pure tone averages.
In 22 patients, there was an overall satisfaction with the
therapy which was seen within one month after the start of
Table 1 The demographics of patients and pure tone average
of the affected ears.
Patient
number
Age
(years)
Sex Side Pure tone average of 0.25,
0.5, 1 and 2 kHz In dB
1 55 F Left 45
2 50 F Left 60
3 46 M Right 53
4 42 F Right 44
5 33 F Bilateral 53 (RT), 62 (LT) (bilateral
grommets)
6 35 M Left 45
7 40 M Bilateral 40 (RT), 33 (LT)
8 46 F Bilateral 55 (RT), 50 (LT) (bilateral
grommets)
9 28 F Right 45
10 28 F Right 39
11 40 M Right 55
12 40 F Left 58
13 55 F Right 45
14 47 M Left 64
15 58 M Right 55
16 53 M Right 57
17 50 F Right 44
18 50 M Left 44
19 45 F Right 53
20 40 M Bilateral 35 (RT), 45 (LT)
21 35 M Bilateral 40 (RT), 35 (LT)
22 57 M Right 55
23 45 M Bilateral 33 (RT), 60 (LT)
24 44 F Bilateral 33 (RT), 67 (LT) gentamycin
therapy
25 30 F Left 70 gentamycin therapy
Table 2 Statistical analysis of the QOL change in response to
treatment, Note: analysis was performed by the of the
Wilcoxon Signed Rank test.
QOL Pre-treatment Post treatment P-value
QOL total score 16.04 ± 6.18 59.28 ± 15.65 <0.0001
Vertigo score 3.321.88 19.445.38 <0.0001
Hearing score 2.601.38 4.881.39 0.01
Physical score 4.361.49 14.123.12 <0.0001
Figure 1 The inverse correlation between the age and quality of
life due to MD.
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sone was 22 out of 25 patients (88%). In three patients (12%),
there was either minimal or no improvement to therapy and it
was considered treatment failure. Two patients had intratym-
panic gentamycin injection later on. The criteria to switch to
gentamycin were persistent in capacitating attacks of vertigo
with poor outcome to dexamethasone. This was done in
patients with predominant unilateral disease with hearing level
more than 60 dB on the affected side and normal or mild hear-
ing loss on the other side, and normal vestibular function by
caloric test (Table 1). The details of gentamycin therapy were
not discussed in this paper.
4.1. Statistical analysis
AWilcoxon Signed Rank test was used to study the changes of
QOL post-treatment in comparison to baseline pre-treatment
QOL in overall and in each group (vertigo, hearing and phys-
ical scores). A Spearmen’s rho test was used the study the cor-
relation between age of patients and their quality of life before
treatment. All data have been processed by the use of statisti-
cal package SPSS ver 18 (Chicago Inc, ILL). A P-value <0.05
was considered statistically signiﬁcant.
As shown in Table 2, there is a statistically signiﬁcant
change in the QOL scores, (especially the and physical scores),
due to local dexamethasone treatment. Statistics also show the
inverse relation between age and the pretreatment QOL as
shown in Fig. 1.5. Discussion
Various etiopathological mechanisms have been postulated to
be at the root of Meniere’s disease (MD), and some data sug-
gest that there may be also an underlying autoimmune factor.9
Immunological abnormalities in Meniere’s disease were
demonstrated by elevated levels of IgG circulating immune
complexes and focal inﬂammation due to deposition of
immune complexes in the endolymphatic sac.10–14 Therefore,
the beneﬁcial effects of steroids could be due to their anti-
inﬂammatory and immunosuppressive effects. They also have
an effect on ionic hemostasis regulation.15
Intratympanic therapies are growing in popularity in the
management of vertigo in Meniere’s disease, and some recom-
mended intratympanic steroids as the ﬁrst surgical option if
medical therapy failed. It was ﬁrst described by Itoh, with
80% of treated patients experiencing improvement in
vertigo.16,17
Other studies have reported good vertigo control in the
short term after local steroid treatment; Sennaroglu et al.
found that 72% of their subjects had satisfactory control of
vertigo after IT dexamethasone treatment.18
Another study demonstrated complete control of vertigo in
82% of those with local steroid treatment versus 57% with pla-
cebo treatment.19
On the other hand, Silverstein et al. claimed that local dex-
amethasone did not show beneﬁt over placebo for improving
vertigo, hearing loss, or tinnitus in a small study of subjects
with late-stage Meniere’s disease.20
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treatment were treated with local steroids, and vertigo
improved in 88% of cases. Similarly, Barrs reported control
of vertigo with one or more courses of local injections of dex-
amethasone in 47% of patients with intractable Meniere’s
disease.21
The dose of local steroids varies among different studies,
some adopted low dose while others used higher dose of
24 mg/ml.225.1. Intratympanic dexamethasone application in Meniere’s
disease—Is it superior to conventional therapy?
In our patients, dexamethasone 8 mgs was injected at the time
of grommet insertion, then 1 and 2 weeks later. The injection
was repeated monthly for 3–6 months. In the intervening time,
low dose dexamethasone eye drops were used and were main-
tained as long as the grommet was in.23
Some presumed that the effect of intratympanic steroids is
transient, as local steroid therapy is more effective in patients
with vertigo and those with shorter duration of illness.
Recently a working group decided to exclude this therapy
modality for Meniere’s disease.24
It has been reported that the efﬁcacy of intratympanic dex-
amethasone decreases with time. For this reason, in our study
the local steroid was maintained at least once weekly as long as
the grommet was in with a total period of treatment ranging
from 6 to 12 months.24,25
All the above studies report improvement in vertigo. Hear-
ing outcomes were not quantitatively addressed in this study
due to lack of post treatment audiogram in some patients. A
study demonstrated 33% hearing improvement, and 20%
hearing deterioration after local steroids.26
Hillman et al. reported a 40% hearing improvement after
local dexamethasone.27
Dexamethasone must act mostly on the endolymphatic sac
and, to a lesser extent, on the stria vascularis and spiral liga-
ment, the known targets of immune response in the inner
ear, to reduce the endolymphatic hydrops and restore the ﬂuid
dynamics of the endolymph.28
Moreover, minimal side effects have been reported related
to the local steroid therapy (mainly tympanic membrane perfo-
ration and inﬂammatory middle ear changes).21
In our series, neither surgery nor local steroids resulted in
complications. The adopted schedule included intermittent
moderate doses (8 mgs), and intervening and maintenance
low doses (dexamethasone eye drops).
Our results concerning vertigo improvement in patients
with intractable MD after intratympanic dexamethasone was
88% with statistically signiﬁcant improvement in the QOLAppendix A. Meniere disease questionnaire:
Q1 – Overall, how much did your MD aﬀect your life?
Before the
treatment
 Completely  Quite a lot  M
After the
treatment:
 Completely  Quite a lot  Mscores. The minimum follow up period was one year, and
the maximum was 5 years (average 2.5) years.
Similarly, a retrospective review assessing long-term (over
two year) vertigo control detailed a 91% success rate with
intermittent intratympanic dexamethasone delivery.29
In 3 patients (No. 23, 24, 25), there was either no response
to local dexamethasone or recurrence of symptoms on pro-
longed treatment course, and intratympanic gentamycin was
done in 2 patients, in whom the disease was predominantly
unilateral with a hearing level of more than 60 dB in the
affected side, with normal or mild hearing loss on the other
side, and normal caloric test. The current interest in intratym-
panic delivery of gentamicin is reviewed. Several studies
demonstrated the efﬁcacy of local gentamycin in relieving ver-
tigo associated with MD (about 85–90%). Hearing loss and
posttreatment disequilibrium remain signiﬁcant concerns, as
the toxic effect is seen in 15–25% of cases. So this therapy car-
ries a greater risk of hearing loss and imbalance.30–34
Because of its cochleotoxic and vestibulotoxic effect, it is
better to reserve gentamycin to cases that failed to respond
to steroids.
The simplest form of intratympanic medication delivery is
via injection into the middle ear either directly with a needle
or through a myringotomy with or without a tympanostomy
tube. This way of drug delivery requires the need for repeat
procedures should dosing of medication be necessary beyond
a one-time application.20 For this reason, a tympanostomy
tube was inserted in our patients for repeated injections and
self-administration of the drug into the middle ear. The tympa-
nostomy tube comes with a small, but real, risk of persistent
perforation of the tympanic membrane upon extrusion of the
tube, otorrhea associated with the presence of the tube, and
the need to keep the ear dry to avoid a middle ear infection.20
The main drawback of this study is the absence of post
treatment audiometric assessment, and the subjective quantiﬁ-
cation of the results. We tried to overcome this by including
the majority of questions in this evaluation questioner.
6. Conclusion
Intratympanic dexamethasone for Meniere’s disease is very
satisfactory if medical treatment fails. It can be implemented
as intermittent moderate dose (8 mgs) and a maintenance
low dose with dexamethasone eye drops, with good vertigo
control and no risk to hearing.
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relationships) for the authors.oderately  Just a little  Not at all
oderately  Just a little  Not at all
Q2 – How much did your MD prevent you from travelling?
Before the
treatment:
 Always  Quite a lot  Moderately  Just a little  Never
After the
treatment:
 Always  Quite a lot  Moderately  Just a little  Never
Q3 – How much were you bothered by the loss of hearing?
Before the
treatment:
 completely  Quite a lot  Moderately  Just a little  Not at all
After the
treatment:
 Completely  Quite a lot  Moderately  Just a little  Not at all
Q4 – How often were you at the doctors oﬃce?
Before the
treatment:
 Far too often  More than most  Routine visits  Hardly ever  Never
After the
treatment:
 Far too often  More than most  Routine visits  Hardly ever  Never
Q5 – I felt my self conﬁdence:
Before the
treatment:
 Terrible  Poor  Average  Average above  Great
After the
treatment:
 Terrible  Poor  Average  Average above  Great
Q6 – My physical health was:
Before the
treatment:
 Terrible  Poor  Average  Good  Ideal
After the
treatment:
 Terrible  Poor  Average  Good  Ideal
Q7 – How much trouble did you have doing daily tasks?
Before the
treatment:
 Maximal  A lot  Some  A little  None
After the
treatment:
 Maximal  A lot  Some  A little  None
Q8 – How disabling were the vertigo episodes?
Before the
treatment:
 Totally
incapacitating
 Interfere with my
life
 I coud manage  Hardly ever aﬀected
me
 None
After the
treatment:
 Totally
incapacitating
 Interferewith my
life
 I coud manage  Hardly ever aﬀected
me
 None
Q9 – Did you have tinnitus?
Before the
treatment:
 Yes, it drove me
crazy
 Often  Sometimes  Rarely  Never
After the
treatment:
 Yes, it drove me
crazy
 Often  Sometimes  Rarely  Never
Q10 – Did you have a problem remembering things?
Before the
treatment:
 All the time  Often  Sometimes  Rarely  Never
After the
treatment:
 All the time  Often  Sometimes  Rarely  Never
Q11 – Did you have diﬃculty walking in a straight line?
Before the
treatment:
 All the time  Often  Sometimes  Rarely  Never
After the
treatment
 All the time  Often  Sometimes  Rarely  Never
Q12 – Did you have a problem with your concentration?
Before the
treatment:
 All the time  Often  Sometimes  Rarely  Never
After the
treatment:
 All the time  Often  Sometimes  Rarely  Never
Q13 – Did you feel depressed?
Before the
treatment:
 All the time  Often  Sometimes  Rarely  Never
After the
treatment:
 All the time  Often  Sometimes  Rarely  Never
(continued on next page)
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Q14 – How much imbalance did you have in-between Meniere’s attacks?
Before the
treatment:
 Extremely poor
balance
 Quite a lot  A moderate
amount
 A little bit  None
After the
treatment:
 Extremely poor
balance
 Quite a lot  A moderate
amount
 A little bit  None
Q15 – How often were your activities impaired?
Before the
treatment:
 I could not do
anything
 More often than
not
 A moderate
amount
 A little bit  Never
After the
treatment:
 I could not do
anything
 More often than
not
 A moderate
amount
 A little bit  Never
Q16 – How much unsteadiness did you have when you were having a Meniere attack?
Before the
treatment:
 Extremely poor
balance
 Quite a lot  A moderate
amount
vA little bit  None
After the
treatment:
 Extremely poor
balance
 Quite a lot  A moderate
amount
 A little bit  None
Q17 – Did your MD aﬀtect your job?
Before the
treatment:
 I thought of retiring  Often  Occasionally  Rarely  Never, or I don’t work
After the
treatment:
 I thought of retiring  Often  Occasionally  Rarely  Never, or I don’t work
Q18 – Approximately how often did you have your MD?
Before the
treatment:
 Daily  Weekly  Monthly  Rarely  Never
After the
treatment:
 Daily  Weekly  Monthly  Rarely  Never
Q19 – How severe were your worst Meniere attacks?
Before the
treatment:
 Totally
incapacitating
 Severe  Bothersome  Not bad  Barely noticeable/no
attack
After the
treatment:
 Totally
incapacitating
 Severe  Bothersome  Not bad  Barely noticeable/no
attack
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